California research team publishes promising results for a universal peptide-based cancer vaccine

SANTA CLARA, Calif., April 5 / PRNewswire / – A team of researchers from Dr. Ing. The Rath Research Institute in California has developed a cancer vaccine that reduces tumor growth. This peptide-based vaccine targets specific enzymes called metalloproteinases (MMPs), which are responsible for tumor growth, metastasis and blood vessels in tumors (angiogenesis). Dr. Rath's research team has shown that the test mice vaccinated with peptides containing specific sequences of MMP-2 and MMP-9, then infected with melanoma cancer cells, exhibited an average tumor reduction about 76% compared to unvaccinated mice. Animals in the control group. Remarkably, some vaccinated animals have not developed any cancer at all.

The study was published in October 2018 in the online Journal of Cell Medicine and Natural Health.

Cancer is still the second largest epidemic in the world. The disease causes more than 7 million deaths each year. This new therapeutic approach has the potential to significantly modify these statistics. Compared to monoclonal antibodies (Mabs) or recently developed biosimilar molecules as anti-cancer agents, the anti-MMP vaccine approach promises to be much more effective and affordable in the global fight against the disease . While Mabs / biosimilars target a specific type of cancer, the MMP vaccine can combat all types of cancer. Another advantage is that, unlike Mabs / Biosimilars, in which an injection usually has to be performed once or twice a month, the anti-MMP vaccine should be injected once and vaccination after several years. would be necessary.

The anti-MMP vaccine, if successfully completed, could be offered to patients from national or international health facilities at a reasonable cost.

To make this valuable technology affordable for the majority of patients and nations around the world, the Dr. Rath Research Institute has sought patent protection in many countries. The institute is seeking public and governmental research institutions and other non-profit institutions to develop with them this promising technology, with the aim of successfully treating, fighting preventively and possibly developing new technologies. eliminate cancer.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-hu man-metalloproteinases-mmps with anti-tumor efficacy in vitro and in vivo /

U.S. Patent Nos. 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

OTS: Dr. med. Press room of the Rath Research Institute: http://www.presseportal.de/nr/132709 via RSS: http://www.presseportal.de/rss/pm_132709.rss2

Press contact: Dr. med. Alexandra Niedzwiecki CEO Rath Research Institute Email: [email protected]